胃肠道间质瘤辅助治疗的已知与已知未知因素

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.

作者信息

Martínez-Marín Virginia, Maki Robert G

机构信息

Medical Oncology Service, Hospital Universitario La Paz, P° de la Castellana, 261, Madrid 28046, Spain.

Tisch Cancer Institute, Department of Medicine, Mt Sinai Medical Center, 1 Gus Levy Place, New York, NY 10029-6574, USA.

出版信息

Gastroenterol Clin North Am. 2016 Sep;45(3):477-86. doi: 10.1016/j.gtc.2016.04.006.

DOI:10.1016/j.gtc.2016.04.006

PMID:27546844

Abstract

The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib. In the adjuvant setting, imatinib is usually given for 3 years postoperatively to patients with higher-risk primary tumors that are completely resected. In this review, issues regarding GIST adjuvant therapy are discussed. It is hoped this review will help the reader understand the present standard of care to improve upon it in years to come.

摘要

胃肠道间质瘤（GIST）治疗的前15年已产生了针对转移性疾病的3种治疗方案：伊马替尼、舒尼替尼和瑞戈非尼。在辅助治疗中，对于完全切除的高危原发性肿瘤患者，通常在术后给予伊马替尼3年治疗。在本综述中，将讨论有关GIST辅助治疗的问题。希望本综述能帮助读者了解目前的治疗标准，以便在未来几年对其进行改进。